Since the emergence of the COVID-19 pandemic, our understanding of the virus and its effects has continually evolved. While the acute phase of the illness is well-documented, there is growing recognition of a phenomenon known as “long-term COVID-19,” which refers to persistent symptoms lasting beyond the acute phase of the infection. A new study published in Nature Medicine chronicles the concept of long-term COVID-19, its symptoms, and the individuals most likely to be affected. This post explores the heightened risk of medical conditions associated with this condition, backed by relevant research and support from scientific and medical organizations. Defining Long-Term COVID-19 Long-term COVID-19, or “post-acute sequelae of SARS-CoV-2 infection” (PASC), is a condition where individuals experience a range of symptoms for weeks or months after

In the ever-evolving landscape of the COVID-19 pandemic, a new chapter has emerged with the identification of EG.5, a subvariant of the Omicron variant – also known as Eris. This discovery has raised questions and concerns globally, prompting health authorities and scientists to delve into its characteristics, spread, precautions, and treatment strategies. Discovery and Identification: Where did Eris Originate? Eris, a descendant of the Omicron variant XBB.1.9.2, was identified in China in February 2023, underscoring the virus’s ability to transform continuously. It has become the dominant strain worldwide due to a mutation that allows it to sidestep antibodies developed by the immune system in response to earlier variants and vaccines. Eris’s Arrival in the United States: A Closer Look Following its initial identification, Eris rapidly